Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Sees Significant Growth in Short Interest

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 173,900 shares, an increase of 58.4% from the October 31st total of 109,800 shares. Currently, 3.6% of the shares of the stock are sold short. Based on an average daily volume of 76,900 shares, the short-interest ratio is presently 2.3 days.

Brainstorm Cell Therapeutics Stock Performance

NASDAQ BCLI remained flat at $1.74 on Friday. 78,671 shares of the company’s stock traded hands, compared to its average volume of 59,998. Brainstorm Cell Therapeutics has a 1 year low of $1.05 and a 1 year high of $11.89. The stock’s fifty day simple moving average is $2.03 and its 200-day simple moving average is $4.37. The company has a market capitalization of $9.92 million, a price-to-earnings ratio of -0.36 and a beta of 0.40.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.